ES2212304T3 - Agente radioprotector para peptidos marcado con un radioisotopo. - Google Patents

Agente radioprotector para peptidos marcado con un radioisotopo.

Info

Publication number
ES2212304T3
ES2212304T3 ES98928875T ES98928875T ES2212304T3 ES 2212304 T3 ES2212304 T3 ES 2212304T3 ES 98928875 T ES98928875 T ES 98928875T ES 98928875 T ES98928875 T ES 98928875T ES 2212304 T3 ES2212304 T3 ES 2212304T3
Authority
ES
Spain
Prior art keywords
povidone
composition
composition according
peptide
radioisotope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98928875T
Other languages
English (en)
Spanish (es)
Inventor
Dan Shochat
Albert S. K. Chan
Michael J. Buckley
David Colcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coulter Pharmaceutical Inc
Original Assignee
Coulter Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coulter Pharmaceutical Inc filed Critical Coulter Pharmaceutical Inc
Application granted granted Critical
Publication of ES2212304T3 publication Critical patent/ES2212304T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES98928875T 1997-06-03 1998-06-03 Agente radioprotector para peptidos marcado con un radioisotopo. Expired - Lifetime ES2212304T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4838797P 1997-06-03 1997-06-03
US48387P 1997-06-03
US08/918,525 US5961955A (en) 1997-06-03 1997-08-21 Radioprotectant for peptides labeled with radioisotope
US918525 1997-08-21

Publications (1)

Publication Number Publication Date
ES2212304T3 true ES2212304T3 (es) 2004-07-16

Family

ID=26726075

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98928875T Expired - Lifetime ES2212304T3 (es) 1997-06-03 1998-06-03 Agente radioprotector para peptidos marcado con un radioisotopo.

Country Status (14)

Country Link
US (2) US5961955A (https=)
EP (1) EP1003560B1 (https=)
JP (1) JP4291417B2 (https=)
AT (1) ATE249845T1 (https=)
AU (1) AU743823B2 (https=)
CA (1) CA2290987A1 (https=)
DE (1) DE69818272T2 (https=)
DK (1) DK1003560T3 (https=)
ES (1) ES2212304T3 (https=)
IL (1) IL133271A (https=)
NO (1) NO315693B1 (https=)
NZ (1) NZ502029A (https=)
PT (1) PT1003560E (https=)
WO (1) WO1998055154A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
ATE259247T1 (de) 1998-06-02 2004-02-15 Dow Global Technologies Inc Radiojodierte phenole für brachytherapie
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
KR100330733B1 (ko) * 1999-11-30 2002-04-03 노광 폴리에틸렌글리콜포스페이트, 그의 합성방법 및 그를방사능보호제로 사용하는 방법
AU2002211232B2 (en) * 2000-09-15 2006-10-19 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
JP2004529884A (ja) * 2001-02-26 2004-09-30 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 金属放射性医薬のためのアスコルビン酸類似体
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7238338B1 (en) 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
AU2003248679A1 (en) * 2002-06-14 2003-12-31 Actinium Pharmaceuticals Ltd. Treating disease using radium-225
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
KR20110140143A (ko) 2002-11-26 2011-12-30 애보트 바이오테라퓨틱스 코포레이션 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체
EP1444990A1 (en) * 2003-02-07 2004-08-11 Amersham plc Improved Radiometal Complex Compositions
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007021825A2 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
KR20090041391A (ko) * 2006-07-24 2009-04-28 테트랄로직 파마슈티칼스 이량체성 iap 길항제
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CL2007002166A1 (es) * 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5297815B2 (ja) 2007-01-26 2013-09-25 株式会社ポーラファルマ 医薬組成物
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
AU2009220244B2 (en) 2008-02-29 2014-10-09 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
KR20110097772A (ko) * 2008-11-17 2011-08-31 제넨테크, 인크. 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
KR101602992B1 (ko) 2009-04-15 2016-03-11 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
CN102858752B (zh) 2010-02-08 2018-10-16 兰休斯医疗成像公司 用于合成显像剂和其中间体的方法和装置
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
JP2016510342A (ja) * 2013-02-15 2016-04-07 トーマス・ジェファーソン・ユニバーシティThomas Jefferson University 腫瘍画像化のためのキット
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US10610807B2 (en) * 2014-01-17 2020-04-07 Repligen Corporation Sterilizing chromatography columns
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
HUE071169T2 (hu) 2016-03-07 2025-08-28 Actinium Pharmaceuticals Inc Stabilizált, radioaktívan jelölt anti-CD45 immunglobulin-készítmények
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
US12599669B2 (en) 2019-04-23 2026-04-14 Amgen Inc. Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations
WO2022265912A1 (en) 2021-06-16 2022-12-22 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
CN121532218A (zh) 2023-06-16 2026-02-13 普罗热尼奇制药公司 前列腺特异性膜抗原(psma)放射性标记抑制剂[18f]dcfpyl的改进的合成

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE933885C (de) * 1952-06-22 1955-10-06 Helmut Richard Dr Kanitz Verfahren zur Herstellung kolloidaler Loesungen radioaktiver Metalle wie radioaktiver Goldisotope
US4421735A (en) * 1980-04-17 1983-12-20 The Massachusetts General Hospital Radiolabeled diagnostic compositions and method for making the same
US4427631A (en) * 1982-05-27 1984-01-24 Euroceltique, S.A. Povidone irradiation
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
EP0111414A3 (en) * 1982-12-08 1985-05-02 Mallinckrodt, Inc. (a Delaware corporation) Radiographic imaging agents
US4676979A (en) * 1984-12-31 1987-06-30 Eastern Virginia Medical Authority/Med. Ctr. Hosp. Method of protecting animals against ionizing radiation
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
RO103925B1 (ro) * 1989-02-27 1992-04-26 Institutul De Chimie Macromoleculara "P.Poni" Derivat de polivinilpirolidona si procedeu de preparare
WO1991004057A1 (en) * 1989-09-22 1991-04-04 Neorx Corporation Stable therapeutic radionuclide compositions and methods for preparation thereof
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
WO1993002652A2 (en) * 1991-08-01 1993-02-18 Hybritech Incorporated Modified haptens useful as imaging and therapeutic agents
DK0600992T3 (da) * 1991-08-29 2000-10-09 Mallinckrodt Medical Inc Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner
ATE132842T1 (de) * 1992-04-30 1996-01-15 Amersham Int Plc Formulierungen von radiomarkierten verbindungen
CA2120023A1 (en) * 1992-07-28 1994-02-03 Noriaki Uenishi Immunoconjugate
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope

Also Published As

Publication number Publication date
US6338835B1 (en) 2002-01-15
EP1003560A1 (en) 2000-05-31
IL133271A (en) 2004-06-01
NZ502029A (en) 2001-12-21
NO995906L (no) 1999-12-03
EP1003560B1 (en) 2003-09-17
WO1998055154A1 (en) 1998-12-10
AU8057098A (en) 1998-12-21
DK1003560T3 (da) 2003-12-01
NO315693B1 (no) 2003-10-13
JP2002516612A (ja) 2002-06-04
CA2290987A1 (en) 1998-12-10
AU743823B2 (en) 2002-02-07
IL133271A0 (en) 2001-04-30
US5961955A (en) 1999-10-05
NO995906D0 (no) 1999-12-02
ATE249845T1 (de) 2003-10-15
DE69818272T2 (de) 2004-07-01
DE69818272D1 (de) 2003-10-23
WO1998055154A9 (en) 1999-04-08
JP4291417B2 (ja) 2009-07-08
PT1003560E (pt) 2004-02-27

Similar Documents

Publication Publication Date Title
ES2212304T3 (es) Agente radioprotector para peptidos marcado con un radioisotopo.
EP0670736B1 (en) Labelled interleukin-8 and medical uses thereof
Abrams et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats
US5605671A (en) Radiolabeled neutrophil activating peptides for imaging
PL204239B1 (pl) Sposób znakowania promieniotwórczego proteiny lub peptydu za pomoca itru-90
CA2279349C (en) Ascorbate-stabilized radiopharmaceutical method and composition
van der Laken et al. Imaging of infection in rabbits with radioiodinated interleukin-1 (α and β), its receptor antagonist and a chemotactic peptide: a comparative study
Hens et al. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands
Vaidyanathan et al. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate
US20100047167A1 (en) Combination therapy in the treatment of cancer
KR20110022743A (ko) 연조직 질환의 방사선 치료에 사용하기 위한 토륨-227
Shi et al. Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer
Singh et al. A simplified kit for instant preparation of technerium-99m human immunoglobulin-G for imaging inflammatory foci
US20240261445A1 (en) Precision radiopharmaceutical therapy of lymphoma and other diseases
RU2698101C2 (ru) Радиофармацевтическая композиция для терапии воспалительных заболеваний суставов на основе радионуклида 188Re и микросфер альбумина крови человека, а также состав и способ её получения
O'Donnell et al. Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma
Akgun et al. Radiopharmaceuticals and their quality control
PL224367B1 (pl) Farmaceutyczny zestaw na bazie gammaglobuliny ludzkiej normalnej
AU2008319468A1 (en) Radiolabeled monoclonal antibodies, methods of preparation using TCEP, and uses thereof